Shares of Alvotech jumped 10.8% to ISK 522.00 after management reaffirmed full-year targets and declared that production had returned to normal following facility upgrades — a move that asks investors to look past a weak first half and bet on a sharp back-loaded recovery. Alvotech Stock Pops 10% on Promise of a Big Second Half — Can the Factory Catch Up Fast Enough to Deliver?
Shares of Alvotech surged 10.8% to ISK 522.00 after management reaffirmed full-year targets and declared its Reykjavik factory back online, asking investors to trust that a dismal first half will be dwarfed by a dramatic second-half ramp. The first-half results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site. The stock had shed roughly 4.5% over the prior five sessions, so the rally signals genuine relief — but the math ahead is daunting.
The First Half Left a Deep Hole to Fill. Q1 revenue came in at just $105.9 million, down from $132.8 million a year earlier. Combined first-half adjusted revenue was only $211.9 million against adjusted EBITDA of $46.9 million. To hit the low end of the $650 million revenue guide, Alvotech must generate roughly $438 million in the second half — more than double first-half output. That's a steep ask for a company whose full-year 2025 revenue was $593 million, with Q4 at $173 million representing the best quarter.
The Factory Fix Isn't the Only Catalyst Management Is Banking On. Manufacturing output returned to planned operating levels by end of Q2 2026. But the ramp also depends on regulatory wins: Alvotech resubmitted U.S. applications for copycat versions of Simponi and Eylea, with FDA decisions expected in Q4 2026.
The low end of the revenue range assumes no revenues from new U.S. launches in 2026 — meaning any approval upside is gravy, but delays could still dent sentiment.
Cash Is Tighter Than It Looks. Cash stood at $142.8 million at the end of the first half. To bridge the gap, the company raised roughly $165 million through an equity offering and private placement and secured a new $75 million term loan. That totals $240 million in new capital — welcome liquidity, but the equity raise dilutes existing shareholders.
The Pipeline Is Broad, but Execution Risk Is Real. Alvotech already markets five biosimilars globally and has 13 disclosed candidates in development spanning autoimmune, eye, bone, respiratory, and cancer therapies.
Analysts project $1.4 billion in revenue and $538.9 million in earnings by 2028, requiring 36.7% yearly revenue growth. Today's rally prices in faith that the factory fix was the bottleneck, not the ceiling. Shareholders will find out by year-end whether that bet was right.